FindTrial
Sign In

Epigenetic Study on Huoling Shengji Granules in the Treatment of Amyotrophic Lateral Sclerosis

Epigenetic Study on Huoling Shengji Granules in the Treatment of Amyotrophic Lateral Sclerosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026000283
Enrollment
Unknown
Registered
2026-02-03
Start date
2026-02-13
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis

Interventions

The Huoling Shengji group:Subjects administered Huoling Shengji Granules in the Phase III clinical trial (Protocol No.: HLSJ-2024-01).
Placebo group:Subjects administered Huoling Shengji Granules placebo in the Phase III clinical trial (Protocol No.: HLSJ-2024-01).

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Subjects participating in the Phase III clinical trial of Huoling Shengji Granules for the treatment of amyotrophic lateral sclerosis (Protocol No.: HLSJ-2024-01) voluntarily take part in this study and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Differential 5-hydroxymethylcytosine markers;—

Countries

China

Contacts

Public ContactDongsheng Fan

Peking University Third Hospital

dsfan@sina.com010-82265032

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026